All articles by Sofia Karadima

Sofia Karadima

Sofia Karadima is a senior editor and researcher at Investment Monitor, focusing on financial and business services, and ESG investing. She previously covered institutional investment across private markets for financial news and research provider Acuris. She has reported on private equity, venture capital, private debt and infrastructure, among other topics. Sofia is currently based in London, after living in Chile, Denmark, Spain and Greece.

CRO consolidation: is the clinical trials industry reaching a tipping point?

The M&A trend among CROs and clinical service providers raises questions about sustainability and impact on their pharma clients.

Foreign direct investment in clinical trials revs up after pandemic hit the breaks

FDI clinical trial projects grew by 16% in 2021, with the sector attracting more projects than it did prior the Covid-19 pandemic.

FDI drivers in 2022: ESG

The global race to net zero has turned ESG into one of the most important drivers of FDI in the post-Covid world.

FDI in pharma: the state of play

The pharmaceutical industry suffered a dip in FDI in 2020 as the Covid-19 pandemic hit, but did any countries manage to avoid this drop?